Literature DB >> 31271515

Discoidin domain receptors: A promising target in melanoma.

Coralie Reger de Moura1,2, Maxime Battistella3,4,5, Anjum Sohail6, Anne Caudron1, Jean Paul Feugeas4,7,8, Marie-Pierre Podgorniak2, Cecile Pages9, Sarra Mazouz Dorval4,10, Oren Marco4,10, Suzanne Menashi11,12, Rafael Fridman6, Celeste Lebbé1,4,9, Samia Mourah1,2,4, Fanélie Jouenne1,2,4.   

Abstract

The discoidin domain receptor 1 (DDR1) is a member of the receptor tyrosine kinase family that signals in response to collagen and that has been implicated in cancer progression. In the present study, we investigated the expression and role of DDR1 in human melanoma progression. Immunohistochemical staining of human melanoma specimens (n = 52) shows high DDR1 expression in melanoma lesions that correlates with poor prognosis. DDR1 expression was associated with the clinical characteristics of Clark level and ulceration and with BRAF mutations. Downregulation of DDR1 by small interfering RNA (siRNA) in vitro inhibited melanoma cells malignant properties, migration, invasion, and survival in several human melanoma cell lines. A DDR tyrosine kinase inhibitor (DDR1-IN-1) significantly inhibited melanoma cell proliferation in vitro, and ex vivo and in tumor xenografts, underlining the promising potential of DDR1 inhibition in melanoma.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  discoidin domain receptor 1; melanoma; prognosis; therapeutic target; tumor progression

Mesh:

Substances:

Year:  2019        PMID: 31271515     DOI: 10.1111/pcmr.12809

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  8 in total

Review 1.  Complex roles of discoidin domain receptor tyrosine kinases in cancer.

Authors:  V Mehta; H Chander; A Munshi
Journal:  Clin Transl Oncol       Date:  2021-02-25       Impact factor: 3.405

Review 2.  The Dynamic Interaction between Extracellular Matrix Remodeling and Breast Tumor Progression.

Authors:  Jorge Martinez; Patricio C Smith
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

3.  Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.

Authors:  Margaux Sala; Nathalie Allain; Mélanie Moreau; Arnaud Jabouille; Elodie Henriet; Aya Abou-Hammoud; Arnaud Uguen; Sylvaine Di-Tommaso; Cyril Dourthe; Anne-Aurélie Raymond; Jean-William Dupuy; Emilie Gerard; Nathalie Dugot-Senant; Benoit Rousseau; Jean-Phillipe Merlio; Anne Pham-Ledart; Béatrice Vergier; Sophie Tartare-Deckert; Violaine Moreau; Frédéric Saltel
Journal:  Oncogene       Date:  2022-03-23       Impact factor: 9.867

4.  Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma.

Authors:  Wei Dai; Shenglan Liu; Shubo Wang; Li Zhao; Xiao Yang; Jingfeng Zhou; Yun Wang; Jing Zhang; Ping Zhang; Ke Ding; Yangqiu Li; Jingxuan Pan
Journal:  Signal Transduct Target Ther       Date:  2021-05-12

5.  Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation.

Authors:  William A Denny; Jack U Flanagan
Journal:  Biomolecules       Date:  2021-11-10

6.  Cabozantinib Is Effective in Melanoma Brain Metastasis Cell Lines and Affects Key Signaling Pathways.

Authors:  Trond Are Mannsåker; Tuyen Hoang; Synnøve Nymark Aasen; Ole Vidhammer Bjørnstad; Himalaya Parajuli; Terje Sundstrøm; Frits Alan Thorsen
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

Review 7.  Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.

Authors:  Ana Popovic; Sophie Tartare-Deckert
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

8.  Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma.

Authors:  Marcel Deckert; Sophie Tartare-Deckert; Ilona Berestjuk; Margaux Lecacheur; Alexandrine Carminati; Serena Diazzi; Christopher Rovera; Virginie Prod'homme; Mickael Ohanna; Ana Popovic; Aude Mallavialle; Frédéric Larbret; Sabrina Pisano; Stéphane Audebert; Thierry Passeron; Cédric Gaggioli; Christophe A Girard
Journal:  EMBO Mol Med       Date:  2021-12-27       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.